Compare · HRTX vs SCLX
HRTX vs SCLX
Side-by-side comparison of Heron Therapeutics Inc. (HRTX) and Scilex Holding Company (SCLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. HRTX focuses on Biotechnology: Pharmaceutical Preparations, while SCLX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- HRTX is the larger of the two at $58.3M, about 4.8x SCLX ($12.1M).
- HRTX has hit the wire 14 times in the past 4 weeks while SCLX has been quiet.
- Both have 6 recent analyst ratings on file.
- Company
- Heron Therapeutics Inc.
- Scilex Holding Company
- Price
- -
- -
- Market cap
- $58.3M
- $12.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 14
- 0
- Recent ratings
- 6
- 6
Heron Therapeutics Inc.
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Latest HRTX
- Chief Operating Officer Hensley Mark Earl converted options into 31,250 shares and covered exercise/tax liability with 8,889 shares, increasing direct ownership by 12% to 201,683 units (SEC Form 4)
- SEC Form DEFA14A filed by Heron Therapeutics Inc.
- SEC Form 10-Q filed by Heron Therapeutics Inc.
- Heron Therapeutics Announces Third Quarter 2026 Financial Results
- SEC Form DEFA14A filed by Heron Therapeutics Inc.
- Heron Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Heron Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
- Chief Executive Officer Collard Craig A converted options into 84,809 shares and covered exercise/tax liability with 20,652 shares, increasing direct ownership by 7% to 931,086 units (SEC Form 4)
- EVP, Chief Financial Officer Duarte Ira converted options into 25,230 shares and covered exercise/tax liability with 7,177 shares, increasing direct ownership by 6% to 302,724 units (SEC Form 4)
Latest SCLX
- DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
- Scilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13D/A filed by Scilex Holding Company
- Large owner Scilex Holding Co disposed of $15,755,000 worth of shares (50,000,000 units at $0.32), decreasing direct ownership by 23% to 163,766,229 units (SEC Form 4)
- SEC Form 10-Q filed by Scilex Holding Company
- JP 3E Holdings, Inc. Appoints Henry Ji, Ph.D., Stephen Ma and Jaedong Yoon to Board of Directors
- Scilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Scilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
- Large owner Sclx Stock Acquisition Jv Llc disposed of 500,000 shares, decreasing direct ownership by 34% to 958,263 units (SEC Form 4)
- Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026